Details of the Drug Combinations

General Information of This Drug (ID: DM62UHC)

• Drug Name: Meropenem (DM62UHC)
• Synonyms: MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid

Indication

Bacterial infection; ICD 11: 1A00-1C4Z; Status: Approved [1]; Meningococcal meningitis; ICD 11: N.A.; Status: Approved [2]; Peritonitis; ICD 11: N.A.; Status: Approved [2]; Pneumococcal meningitis; ICD 11: N.A.; Status: Approved [2]; Pseudomonas aeruginosa infectious disease; ICD 11: N.A.; Status: Approved [2]

• Therapeutic Class: Antibiotics
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Meropenem + Colistimethate	DCUIHEZ	Colistimethate	Gram-Negative Bacterial Infections	[3]
Meropenem + Amoxicillin	DCVF97B	Amoxicillin	Pulmonary Tuberculosis	[4]
Linezolid + Meropenem	DC1XM77	Linezolid	Healthcare-associated Pneumonia (HCAP)	[5]
Meropenem + Plazomicin	DCDIRKH	Plazomicin	Bloodstream Infections (BSI) Due to CRE	[6]
Meropenem + Tigecycline	DCL12QF	Tigecycline	Bloodstream Infections (BSI) Due to CRE	[6]
Meropenem + Levofloxacin	DC7FRNK	Levofloxacin	Complicated Urinary Tract Infection	[7]
Ceftazidime + Meropenem	DC6SBHH	Ceftazidime	Cystic Fibrosis	[8]
Ertapenem + Meropenem	DCCPIYG	Ertapenem	Urinary Tract Infections	[9]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Meropenem + Vaborbactam	DCOGD4K	Vaborbactam	Urinary tract infection; Intra-abdominal infection	[10]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] Meropenem FDA Label
• [3] ClinicalTrials.gov (NCT01732250) Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem
• [4] ClinicalTrials.gov (NCT05896930) Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
• [5] ClinicalTrials.gov (NCT03032380) Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
• [6] ClinicalTrials.gov (NCT01970371) A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE). U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT02486627) A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
• [8] ClinicalTrials.gov (NCT01044719) Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
• [9] ClinicalTrials.gov (NCT03891433) Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
• [10] FDA Drug Development and Drug Interactions